CYSVIEW KIT Drug Patent Profile

Which patents cover Cysview Kit, and when can generic versions of Cysview Kit launch?

Cysview Kit is a drug marketed by Photocure Asa and is included in one NDA. There are three patents protecting this drug.

This drug has thirty-nine patent family members in twenty countries.

The generic ingredient in CYSVIEW KIT is hexaminolevulinate hydrochloride. One supplier is listed for this compound. Additional details are available on the hexaminolevulinate hydrochloride profile page.

DrugPatentWatch^® Generic Entry Outlook for Cysview Kit

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 19, 2036. This may change due to patent challenges or generic licensing.

There have been two patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

Indicators of Generic Entry

Summary for CYSVIEW KIT

International Patents:	39
US Patents:	3
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Raw Ingredient (Bulk) Api Vendors:	65
Clinical Trials:	4
Patent Applications:	235
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for CYSVIEW KIT
DailyMed Link:	CYSVIEW KIT at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for CYSVIEW KIT

NDA:

022555

Dosage:

FOR SOLUTION;INTRAVESICAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for CYSVIEW KIT

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Johns Hopkins University	PHASE3
Photocure ASA	PHASE3
Dr. Te Vuong	Phase 2

See all CYSVIEW KIT clinical trials

US Patents and Regulatory Information for CYSVIEW KIT

CYSVIEW KIT is protected by three US patents.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010		RX	Yes	Yes
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010		RX	Yes	Yes
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010		RX	Yes	Yes

Expired US Patents for CYSVIEW KIT

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010
Photocure Asa	CYSVIEW KIT	hexaminolevulinate hydrochloride	FOR SOLUTION;INTRAVESICAL	022555-001	May 28, 2010

International Patents for CYSVIEW KIT

When does loss-of-exclusivity occur for CYSVIEW KIT?

Based on analysis by DrugPatentWatch, the following patents block generic entry in the countries listed below:

Australia

Brazil

Canada

China

Denmark

European Patent Office

Finland

Japan

Poland

Russian Federation

South Korea

Spain

United Kingdom

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

See the table below for additional patents covering CYSVIEW KIT around the world.

Country	Patent Number	Title	Estimated Expiration
Australia	2016372573
Brazil	112018012009	terapia neoadjuvante para câncer de bexiga
Canada	3008551	TRAITEMENT NEOADJUVANT DU CANCER DE LA VESSIE (NEOADJUVANT THERAPY FOR BLADDER CANCER)
China	108601836	用于膀胱癌的新辅助疗法 (Neoadjuvant therapy for bladder cancer)
China	119345359	用于膀胱癌的新辅助疗法 (Novel adjuvant therapy for bladder cancer)

Supplementary Protection Certificates for CYSVIEW KIT

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
0820432	SPC024/2002	Ireland		SPC024/2002: 20041230, EXPIRES: 20160614
0820432	SPC/GB02/038	United Kingdom		PRODUCT NAME: METHYL AMINOLEVULINATE, OPTIONALLY IN THE FORM OF A SALT, PREFERABLY METHYL AMINOLEVULINATE HYDROCHLORIDE; REGISTERED: SE 16338 20010615; UK PL18952/0002 20020408
0820432	300176	Netherlands		300176, 20160308, EXPIRES: 20160614
0820432	300207	Netherlands		300207, 20160308, EXPIRES: 20190916
0820432	SPC/GB05/044	United Kingdom		PRODUCT NAME: HEXYL AMINOLEVULINATE, OPTIONALLY IN THE FORM OF A SALT, PREFERABLY HEXYL AMINOLEVULINATE HYDROCHLORIDE; REGISTERED: SE 19227 20040917; UK PL 18952/0003 20050714

Last updated: June 25, 2026

CYSVIEW Kit market dynamics and financial trajectory: pricing, demand drivers, competition, and exclusivity risk

Cysview (aminolevulinic acid HCl) 1.5 g powder for oral solution + reconstitution system is a hospital-administered diagnostic therapy used in photodynamic diagnosis for “suspected” bladder cancer and marketed as a kit. The financial and market trajectory for Cysview is driven by: (1) durable demand in urology and cystoscopy workflows, (2) payer and hospital formulary pressures typical of niche oncology diagnostics, (3) utilization tied to recurrence surveillance intensity, and (4) competitive intensity from intravesical alternatives and generic/authorized generic risk once relevant U.S. IP protections and exclusivity end. Public financial reporting for the product’s standalone net sales is limited, so forward-looking revenue scenarios hinge on U.S. launch timing of any generic versions and on contract outcomes with large hospital systems and group purchasing organizations.

What is CYSVIEW Kit and how is it used in bladder cancer diagnosis?

Cysview is administered intravesically (instilled into the bladder) after reconstitution of aminolevulinic acid HCl, then illuminated for fluorescence photodynamic diagnosis. Clinically, it is used to improve detection of non–muscle invasive bladder cancer (NMIBC) lesions during cystoscopy, supporting recurrence surveillance and risk-stratified resection planning.

What clinical setting drives routine utilization

• Recurrence surveillance schedules for NMIBC (repeated cystoscopy) drive repeat opportunity.
• Higher-risk NMIBC cohorts increase testing frequency, expanding procedure volumes.
• Institutional protocols and urology practice patterns affect adoption, including fluorescence-guided transurethral resection (TURBT) adoption.

What product form factors affect adoption

• Hospital kit workflow: pharmacy reconstitution and urology instillation coordination.
• Dependence on imaging/illumination setup and staff training.
• Purchase and training tied to diagnosis pathway reimbursement and internal clinical value assessment.

What are the key market dynamics shaping CYSVIEW Kit demand in the US?

Cysview’s market behaves like a procedure-adjacent specialty diagnostic product rather than a chronic therapy. Demand is sensitive to procedure volume, payer coverage, and hospital formulary mechanics.

Coverage, reimbursement, and payer friction

• Diagnostic indication coverage typically depends on payer policies for “photodynamic diagnosis” and related billing practices.
• Hospitals weigh incremental value against budget impact and evidence thresholds in local medical policy.

Hospital procurement and contracting dynamics

• Large health systems negotiate pricing and may limit preferred use to center-of-excellence urology programs.
• Group purchasing organizations (GPOs) and contracting cycles can cause step-change demand shifts when pricing terms are renegotiated.

Utilization dependence on cystoscopy volumes

• Fluids and supply chain variability can disrupt procedure scheduling, creating short-term volatility.
• Seasonal variation in elective procedures can change near-term usage, especially in systems that bundle urology services.

How has CYSVIEW Kit pricing and reimbursement pressure evolved?

Cysview pricing in the U.S. is influenced by niche oncology diagnostics pricing norms and by payer pushback around cost-effectiveness. The product’s pricing power correlates with:

• clinical adoption across TURBT pathways,
• durability of prescribing protocols, and
• lack of close substitution.

Key constraints:

• budget neutrality expectations for added diagnostic steps,
• compressed reimbursement for some outpatient diagnostic workflows,
• internal hospital value analysis panels that may delay adoption.

What competitors substitute for CYSVIEW Kit in photodynamic diagnosis?

Competitive risk typically comes from:

• alternative intravesical diagnostic strategies (including those that do not require the same fluorescence pathway),
• competing photodynamic diagnosis platforms, and
• increased use of other cystoscopy adjuncts when coverage tightens.

How substitution risk is assessed

• Clinical differentiation: sensitivity/specificity in detecting carcinoma in situ and non–muscle invasive lesions.
• Workflow friction: time-to-diagnosis, staffing requirements, and compatibility with existing endoscopy and imaging devices.
• Payer behavior: whether payers reimburse fluorescent diagnosis or restrict coverage.

When does CYSVIEW Kit lose exclusivity in the U.S.?

A complete exclusivity and expiration map requires product-specific patent and exclusivity records (Orange Book and FDA exclusivity data). Without a verified Orange Book listing and FDA exclusivity dataset for the specific Cysview kit/NDC, a precise “loss of exclusivity” date cannot be stated.

What patents protect CYSVIEW Kit in the U.S., and how many are in force?

A complete, accurate count of in-force patents and their expiration dates requires the Orange Book patent list for the exact Cysview kit product and relevant NDC(s). Without confirmed Orange Book entries, the scope, number, and expiration dates of patents cannot be stated.

What patent litigation affects CYSVIEW Kit, including Paragraph IV challenges?

Paragraph IV litigation requires a verifiable record of ANDA filings referencing Cysview and any Hatch-Waxman suits or settlements. Without confirmed litigation and court dockets tied to the exact Cysview product, no accurate timeline or parties can be reported.

What is the Orange Book status of CYSVIEW Kit?

Orange Book status requires retrieval of:

• all listed patents for the relevant Cysview NDC(s),
• patent types (drug substance, drug product, formulation, method of use),
• and FDA exclusivity references (if applicable). Without that confirmed listing, no authoritative status can be provided.

How does CYSVIEW Kit compare with other bladder cancer diagnostic products on market adoption risk?

Cysview adoption is mostly tied to procedure pathway integration and payer coverage for fluorescence-guided diagnosis. Compared with generic-like substitutions, adoption risk is higher when:

• competing diagnostic options reduce workflow burden,
• alternative pathways gain payer coverage,
• or evidence-based clinical guidelines shift toward other adjuncts.

Compared with therapeutics (which face label-driven switching), diagnostic adjuncts can be adopted or discontinued based on protocol updates and budget cycles.

What formulation and manufacturing/IP barriers would block generic CYSVIEW Kit entry?

A generic or biosimilar-like entry for an intravesical diagnostic kit depends on whether protection targets:

• aminolevulinic acid HCl drug substance,
• kit formulation and reconstitution system,
• intravesical administration method or timing (method-of-use),
• manufacturing controls for stability and performance of the reconstituted solution.

Barrier strength correlates with whether listed IP covers method-of-use and whether the kit’s performance is tied to proprietary formulation features.

What biosimilar risk exists for CYSVIEW Kit?

Cysview is a small-molecule drug kit (aminolevulinic acid HCl) used for diagnostic photodynamic imaging, not a biologic. Biosimilar pathways are not applicable.

What generic entry risks exist for CYSVIEW Kit?

Generic entry risk hinges on:

• expiration of all relevant U.S. patents listed in the Orange Book for the specific NDC(s),
• whether any remaining method-of-use patents prevent FDA approval for substitution,
• the strength of any Orange Book “blocking” patents,
• and whether any generic would face authorized launch after a settlement.

Without verified patent and litigation records for Cysview, a launch probability cannot be quantified.

What regulatory milestones drive changes in CYSVIEW Kit market trajectory?

Cysview’s U.S. regulatory path affects label wording, indication coverage, and hospital adoption:

• changes to indication language can alter payer coverage policies,
• supplemental approvals can expand or clarify use cases (procedural adoption impacts).

A complete regulatory timeline requires confirmed FDA review history for the specific Cysview product and label revisions; without that dataset, no accurate milestone list can be compiled.

Which companies are challenging CYSVIEW Kit patents, and what settlements exist?

Identifying challengers and settlement terms requires confirmed Paragraph IV litigation and settlement documents. Without a verified litigation record tied to the exact Cysview kit product, no accurate parties or agreements can be listed.

What does the financial trajectory for CYSVIEW Kit depend on: sales channels, procedure volumes, and payer rates?

Cysview revenue trajectory is a function of:

1. Procedure adoption: number of NMIBC cystoscopy/TURBT cases using photodynamic diagnosis.
2. Net pricing: list price less discounts, rebates, and contract terms with IDNs and payers.
3. Mix shift: shifts toward higher-risk cohorts increase utilization per patient and per surveillance cycle.
4. Persistence: whether urology groups keep fluorescence workflows after early adoption.
5. Competitive and IP events: generic entry timing can compress net pricing quickly.

Revenue exposure framework: downside and upside scenarios

Without verified historic net sales and a full exclusivity/patent expiration schedule, only a structural exposure model can be stated.

Downside drivers

• faster-than-expected protocol shift away from fluorescence diagnosis,
• broader payer edits restricting coverage or increasing patient cost-sharing,
• any approved generic kit launch that triggers price erosion,
• formulary removals in major IDNs.

Upside drivers

• expanded clinical acceptance beyond early adopters,
• stable or improved payer reimbursement for fluorescent diagnosis pathways,
• new evidence supporting broader lesion detection and improved outcomes that increase adoption,
• strong contracting with top hospital systems sustaining share.

Key Takeaways

• Cysview (aminolevulinic acid HCl) is a procedure-adjacent intravesical diagnostic kit; market dynamics track urology cystoscopy/TURBT surveillance volumes more than chronic-dosing behavior.
• Demand is shaped by hospital formulary contracting, payer coverage for photodynamic diagnosis, and workflow integration for fluorescence-guided cystoscopy.
• Financial trajectory depends on net pricing (rebates and IDN contracts), persistence of fluorescence protocols, and any generic or protocol-substitution events after U.S. patent/exclusivity periods end.
• A precise exclusivity-loss date, patent estate size, Orange Book status, and litigation timeline cannot be stated without verified product-specific Orange Book and FDA datasets for Cysview kit NDC(s).

FAQs

1. How do hospital formulary decisions affect CYSVIEW Kit uptake across large health systems?
2. What clinical guideline updates most influence the frequency of photodynamic diagnosis use in NMIBC surveillance?
3. How would a U.S. generic launch for aminolevulinic acid HCl intravesical kits likely impact Cysview net pricing?
4. What billing and coding practices determine payer reimbursement for fluorescent cystoscopy workflows?
5. How does staff training and equipment compatibility impact real-world adoption of Cysview fluorescence diagnosis?

References

1. FDA Orange Book. U.S. Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration.
2. FDA. Drug Approvals and Databases. U.S. Food and Drug Administration.
3. FDA. Drugs@FDA. U.S. Food and Drug Administration.